Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

NCT04504331 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Drug manufacturer decision to terminate development.

Conditions

Breast Cancer
HER2-negative Breast Cancer
ER Positive Breast Cancer
PR-Positive Breast Cancer

Interventions

DRUG: Infigratinib
DRUG: Tamoxifen
DRUG: Omnipaque 350
DRUG: Iopamidol
DIAGNOSTIC_TEST: Computed tomography (CT)

Sponsor

Jennifer Lee Caswell-Jin

Collaborators

[object Object]
[object Object]